Lascufloxacin - Kyorin Pharmaceutical
Alternative Names: KRP-AM1977; KRP-AM1977X; KRP-AM1977Y; Lascufloxacin hydrochloride; LasvicLatest Information Update: 28 Jan 2022
At a glance
- Originator Kyorin; Kyorin Pharmaceutical
- Developer Kyorin Pharmaceutical
- Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Pyrrolidines; Quinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia
- Registered Otorhinolaryngological infections; Respiratory tract infections
- No development reported Kidney disorders; Liver disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Kidney-disorders in Japan (PO)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Liver-disorders in Japan (PO)
- 27 Nov 2020 Registered for Community-acquired pneumonia in Japan (IV, Infusion)